Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain
Citations Over TimeTop 10% of 2014 papers
Abstract
We have identified several series of small molecule inhibitors of TrkA with unique binding modes. The starting leads were chosen to maximize the structural and binding mode diversity derived from a high throughput screen of our internal compound collection. These leads were optimized for potency and selectivity employing a structure based drug design approach adhering to the principles of ligand efficiency to maximize binding affinity without overly relying on lipophilic interactions. This endeavor resulted in the identification of several small molecule pan-Trk inhibitor series that exhibit high selectivity for TrkA/B/C versus a diverse panel of kinases. We have also demonstrated efficacy in both inflammatory and neuropathic pain models upon oral dosing. Herein we describe the identification process, hit-to-lead progression, and binding profiles of these selective pan-Trk kinase inhibitors.
Related Papers
- → Biological effects of TrkA and TrkB receptor signaling in neuroblastoma(2005)130 cited
- → The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition(2012)117 cited
- → The effect of P75 on Trk receptors in neuroblastomas(2011)32 cited
- → Life and Death in Mice Without Trk Neurotrophin Receptors(1995)1 cited
- → Abstract B184: TPX-0005, a highly potent TRK inhibitor, effectively overcomes clinical-resistance TRK mutations including solvent front mutants TRKA G595R, TRKB G639R, and TRKC G623R(2018)